Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Gamida Cell closes $40mm Series F round

Executive Summary

Gamida Cell Ltd. (cell and immunotherapies for cancer) raised $40mm through what appears to be its Series F round. (The funding is the first for the company since closing a $10mm Series E in 2012.) New investor Shavit Capital led and was joined by other first-time buyers VMS Investment Group and Israel Biotech fund, along with returning backers Novartis, Clal Biotechnology, and Israel HealthCare Ventures. Proceeds will support completion of Phase III trials and future commercialization of NiCord, an ex vivo expanded cell graft from umbilical cord stem cells indicated for bone marrow transplantation in blood cancer patients who do not have a fully matched donor.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
    • Gene Therapy, Cell Therapy
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies